CLINICAL TRIALS PROFILE FOR PF-06700841

Clinical Trials for PF-06700841

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT02310750 ↗	A Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06700841, With Bioavailability/Food Effect Investigation	Completed	Pfizer	Phase 1	The main purpose of the study is to determine if PF-06700841 is safe and well tolerated when administered to humans. A secondary purpose is to assess what the body does to PF-06700841 and to assess what PF-06700841 does to the body when given as single and multiple doses. The pharmacokinetic properties of different forms of PF-06700841 may be studied (tablet and solution/suspension forms).
NCT02958865 ↗	Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis	Completed	Pfizer	Phase 2	The purpose of this study is to determine whether PF-06651600 and PF-06700841 are effective in treatment of moderate to severe ulcerative colitis.
NCT02969018 ↗	Study To Evaluate Safety And Efficacy Of PF-06700841 In Subjects With Moderate To Severe Plaque Psoriasis	Completed	Pfizer	Phase 2	The purpose of this study is to determine whether PF-06700841 is safe and effective in the treatment of chronic plaque psoriasis.
NCT02974868 ↗	Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata	Completed	Pfizer	Phase 2	This is a Phase 2a, randomized, double blind, parallel group, multicenter study with an extension period. The study will have a maximum duration of approximately 113 weeks. This includes an up to 5 weeks Screening Period, a 24 week Treatment Period, a 4 week Drug Holiday (#1), an up to 12 month Single Blind (investigator open, sponsor open and subject blind) Extension Period, a 4 week drug holiday (#2), a 6 month Cross Over Open Label Extension Period and a 4 week Follow up Period.
NCT03236493 ↗	Safety and Pharmacokinetic Study of PF-06700841 in Japanese Healthy Volunteers	Completed	Pfizer	Phase 1	This study is a phase 1 study of PF-06700841. PF-06700841 is being developed for treatment of inflammatory bowel disease. The goal of the study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-06700841 after multiple oral doses of PF-06700841 in Japanese healthy volunteers.
NCT03395184 ↗	Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 In Subjects With Moderate To Severe Crohn's Disease	Recruiting	Pfizer	Phase 2	The objectives of this study are to evaluate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06651600 (200 mg for 8 weeks followed by 50 mg for 4 weeks) dosed once daily and PF-06700841 (60 mg for 12 weeks) dosed once daily during an induction period of 12 weeks, followed by an open label extension period at doses of 50 mg and 30 mg of PF 06651600 and PF 06700841, respectively, for 52 weeks.

Clinical Trial Conditions for PF-06700841

Condition Name

Condition Name for
Intervention	Trials
Healthy	3
Healthy Participants	3
Psoriatic Arthritis	1
Cicatricial Alopecia	1

Condition MeSH

Condition MeSH for
Intervention	Trials
Psoriasis	3
Alopecia Areata	2
Alopecia	2
Eczema	1

Clinical Trial Locations for PF-06700841

Trials by Country

Trials by Country for
Location	Trials
United States	155
Canada	24
Australia	22
Japan	19
Italy	15

Trials by US State

Trials by US State for
Location	Trials
Florida	12
California	10
New York	9
Virginia	8
Texas	8

Clinical Trial Progress for PF-06700841

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase	Trials
Phase 2	11
Phase 1	10

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase	Trials
Completed	16
Recruiting	4
Active, not recruiting	1

Clinical Trial Sponsors for PF-06700841

Sponsor Name

Sponsor Name for
Sponsor	Trials
Pfizer	21
Emma Guttman	1

Sponsor Type

Sponsor Type for
Sponsor	Trials
Industry	21
Other	1